Cargando…

Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The increasingly important role of allo-SCT in the management of AML has been underpinned by two important advances. Firstly, improvements in disease risk stratification utilizing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loke, Justin, Vyas, Hrushikesh, Craddock, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083129/ https://www.ncbi.nlm.nih.gov/pubmed/33937080 http://dx.doi.org/10.3389/fonc.2021.666091

Ejemplares similares

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
por: Loke, Justin, et al.
Publicado: (2021)

Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia
por: Manobianco, Steven A., et al.
Publicado: (2022)

The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience
por: Loke, Justin, et al.
Publicado: (2019)

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
por: Craddock, Charles, et al.
Publicado: (2016)

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia
por: Craddock, Charles, et al.
Publicado: (2021)

Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia
por: Ciotti, Giulia, et al.
Publicado: (2022)

The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia
por: Maffini, Enrico, et al.
Publicado: (2022)

Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective
por: Chang, Ying-Jun, et al.
Publicado: (2021)

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies
por: El Achi, Hanadi, et al.
Publicado: (2021)

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Antar, Ahmad I., et al.
Publicado: (2020)

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
por: Vucinic, Vladan, et al.
Publicado: (2020)

Molecular predictors of post-transplant survival in acute myeloid leukemia
por: Qin, Tong, et al.
Publicado: (2017)

Co-management strategies for acute myeloid leukemia patients in the community setting
por: Benton, Christopher, et al.
Publicado: (2022)

MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia
por: Niu, Mingshan, et al.
Publicado: (2019)

Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study
por: Zhou, Wei, et al.
Publicado: (2023)

Molecular Therapeutic Approaches for Pediatric Acute Myeloid Leukemia
por: Tasian, Sarah K., et al.
Publicado: (2014)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Survival, response rates, and post-transplant outcomes in patients with Acute Myeloid Leukemia aged 60-75 treated with high intensity chemotherapy vs. lower intensity targeted therapy
por: Sahasrabudhe, Kieran, et al.
Publicado: (2022)

Post-transplant Complication With TAFRO Features in a Patient With Acute Myeloid Leukemia
por: Yamaguchi, Kyosuke, et al.
Publicado: (2022)

Post-Transplant Maintenance Therapy for Patients with Acute Myeloid Leukemia: Current Approaches and the Need for More Trials
por: Assi, Rita, et al.
Publicado: (2021)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation
por: Liberatore, Carmine, et al.
Publicado: (2023)

Cytomegalovirus Reactivation in Patients With Acute Lymphoblastic Leukemia in Non-transplant Setting
por: Abbas, Mansoor, et al.
Publicado: (2022)

Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies
por: Yanada, Masamitsu, et al.
Publicado: (2022)

Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia
por: Malagola, Michele, et al.
Publicado: (2023)

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
por: de Lima, Marcos, et al.
Publicado: (2018)

Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients
por: Troullioud Lucas, Alexandre G., et al.
Publicado: (2023)

Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia
por: Sanz, Jaime, et al.
Publicado: (2021)

Targeting the Innate Immune System as Immunotherapy for Acute Myeloid Leukemia
por: Curran, Emily, et al.
Publicado: (2015)

Alternative Donor Transplantation for Acute Myeloid Leukemia
por: Bejanyan, Nelli, et al.
Publicado: (2015)

A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia
por: Li, Yuhang, et al.
Publicado: (2021)

Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia
por: Schleicher, Oliver, et al.
Publicado: (2022)

Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Namdaroglu, Sinem, et al.
Publicado: (2019)

Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Murine Models of Acute Myeloid Leukemia
por: Kurtz, Kristen J., et al.
Publicado: (2022)

Vitamin C Deficiency in Patients With Acute Myeloid Leukemia
por: Ottone, Tiziana, et al.
Publicado: (2022)

Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia
por: Chapuis, Nicolas, et al.
Publicado: (2019)

Corrigendum: Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia
por: Schleicher, Oliver, et al.
Publicado: (2022)

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
por: Russell, Nigel H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3i5pmm1rn3n95bolf840o11cjr